Evonile Pharma quarterly results and financials

Evonile Pharma (NOVARTIND)₹1,758+2.61%(6 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (standalone), Evonile Pharma reported sales of ₹104 Cr, up 18.1% from Jun 2025, and net profit of ₹32.07 Cr, up 14.3% year on year. For the year to Mar 2026, sales were ₹353 Cr and net profit ₹93.14 Cr.

Sales (Jun 2026): ₹104 Cr
Net profit (Jun 2026): ₹32.07 Cr
Sales (FY Mar 2026): ₹353 Cr
Net profit (FY Mar 2026): ₹93.14 Cr
EPS (Jun 2026): ₹13.02
Borrowings (Mar 2026): ₹2.99 Cr

Company filings, standalone accounts; latest reported quarter Jun 2026

Evonile Pharma quarterly results

₹ crore unless stated; each column is a quarter.

Evonile Pharma Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	78.91	84.77	80.85	91.87	86.83	92.78	83.80	87.84	89.84	85.85	90.84	104
Expenses	62.13	65.13	70.18	68.20	69.10	67.19	60.12	60.14	66.13	64.12	70.21	69.15
Operating Profit	16.96	19.98	10.99	23.98	17.96	25.97	23.98	26.94	23.97	21.98	20.95	34.92
OPM %	21.0%	23.0%	14.0%	26.0%	21.0%	28.0%	29.0%	31.0%	26.0%	26.0%	23.0%	34.0%
Other Income	16.95	21.91	9.97	9.96	9.96	10.96	10.96	10.96	8.97	8.96	9.97	8.96
Interest	1.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.01	0.00	0.00
Depreciation	1.01	0.00	0.00	1.01	1.01	1.01	1.01	1.01	1.01	0.00	0.00	0.00
Profit before tax	32.06	41.05	21.03	34.03	28.03	35.07	34.05	37.08	33.05	30.06	30.07	43.05
Tax %	27.1%	36.1%	31.1%	24.1%	26.1%	28.1%	14.1%	26.0%	26.1%	46.0%	16.1%	25.0%
Net Profit	24.05	27.05	15.04	26.04	20.04	25.03	29.06	28.07	24.03	16.03	25.04	32.07
EPS (Rs)	9.56	10.74	5.93	10.40	8.26	10.29	11.86	11.17	9.80	6.51	10.21	13.02

Evonile Pharma profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Evonile Pharma Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	689	655	563	490	437	380	399	378	334	355	353	370
Expenses	658	633	571	479	427	356	374	315	271	266	261	270
Operating Profit	33.93	24.96	−5.99	11.99	11.97	26.96	26.98	64.86	64.93	90.91	93.80	102
OPM %	5.0%	3.8%	−1.1%	2.5%	2.8%	7.0%	7.0%	17.0%	19.0%	26.0%	27.0%	27.5%
Other Income	206	70.75	172	77.78	35.88	32.90	−16.94	57.77	61.81	41.83	38.89	36.86
Interest	0.00	1.01	6.02	2.01	6.02	8.02	5.02	2.01	1.01	1.01	1.01	1.01
Depreciation	2.99	3.99	3.01	2.99	12.99	12.01	10.01	6.01	3.01	2.01	2.01	1.01
Profit before tax	237	92.11	158	86.12	29.03	40.04	−4.01	115	123	130	130	136
Tax %	16.1%	38.0%	50.0%	40.1%	65.1%	48.1%	−3.0%	10.1%	31.1%	23.1%	28.1%	—
Exceptional items	0.00	0.00	11.98	0.00	0.00	0.00	−44.89	0.00	1.99	0.00	0.00	—
Net Profit	198	57.08	78.21	52.11	10.01	21.05	−4.01	103	85.22	101	93.14	97.17
EPS (Rs)	61.93	20.29	31.68	20.94	4.07	8.45	−1.50	41.79	34.41	40.82	37.66	39.54
Dividend payout %	15.9%	48.9%	31.9%	47.9%	245.0%	117.9%	−663.1%	112.9%	71.9%	60.9%	0.0%	—

Evonile Pharma balance sheet

₹ crore, at each year end.

Evonile Pharma Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	15.96	15.94	13.95	11.96	11.96	11.97	11.98	11.98	11.96	11.97	11.97	11.96
Reserves	984	1,175	904	719	745	708	699	678	762	731	772	803
Borrowings	0.00	0.00	0.00	0.00	0.00	67.74	61.76	23.91	21.91	6.97	4.98	2.99
Other Liabilities	243	238	229	375	222	288	228	241	185	172	157	156
Total Liabilities	1,243	1,429	1,146	1,107	979	1,076	1,000	956	981	923	946	975
Fixed Assets	8.01	6.01	6.02	5.01	15.03	76.16	64.12	24.05	19.04	7.02	5.01	3.01
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	1,235	1,422	1,140	1,102	964	999	936	932	962	916	941	972
Inventories	100	72.15	88.12	57.08	61.11	59.10	48.03	57.04	55.11	45.07	41.07	53.04
Trade receivables	82.82	49.92	40.93	43.91	45.95	37.96	38.93	44.91	35.94	40.96	39.94	36.95
Cash & equivalents	836	1,121	814	772	610	580	497	516	554	594	646	666
Total Assets	1,243	1,429	1,146	1,107	979	1,076	1,000	956	981	923	946	975

Evonile Pharma cash flow

₹ crore, for each year.

Evonile Pharma Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	−60.10	57.01	−41.02	161	−194	−23.01	−69.11	39.03	45.05	113	75.07	47.05
Cash from investing activity	722	−632	425	69.23	275	56.18	95.32	87.36	−154	33.14	−3.01	18.06
Cash from financing activity	−38.03	−39.03	−332	−268	−30.06	−41.04	−37.08	−36.02	−30.03	−121	−64.13	−64.05
Net cash flow	624	−614	51.13	−38.11	50.18	−9.03	−11.04	90.25	−139	26.07	7.02	0.00
Capex	4.68	2.47	2.79	0.79	14.04	0.99	0.08	0.49	0.30	0.00	0.00	0.33
Free cash flow	−63.84	53.88	−43.92	160	−207	−23.93	−68.81	37.92	44.92	113	74.79	45.92
CFO / OP %	601.0%	398.0%	12.9%	−3,503.1%	−1,210.1%	123.9%	−127.1%	209.9%	64.9%	114.9%	98.9%	86.9%

Evonile Pharma ratios

Working-capital days and returns, by year.

Evonile Pharma Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	34	26	22	27	33	30	36	40	34	44	40	37
Inventory days	103	92	104	84	111	117	119	117	99	82	74	98
Days payable	99	90	88	159	169	146	138	149	109	113	94	102
Cash conversion cycle	40	30	40	−45	−23	3	19	10	26	15	22	36
Working capital days	6	−35	−14	−99	7	−1	62	−23	−37	−59	−45	−46
ROCE %	9.0%	22.0%	9.0%	16.9%	12.0%	5.0%	6.0%	6.0%	15.0%	16.0%	16.9%	16.0%

Evonile Pharma: frequently asked questions

What are the latest quarterly results of Evonile Pharma?

For the Jun 2026 quarter, Evonile Pharma reported sales of ₹104 Cr, up 18.1% year on year and net profit of ₹32.07 Cr, up 14.3% year on year. The operating margin was 34.0%.

What is the annual revenue of Evonile Pharma?

Evonile Pharma's sales for the year to Mar 2026 were ₹353 Cr; over the last twelve months they were ₹370 Cr.

What is the net profit of Evonile Pharma?

Net profit for the year to Mar 2026 was ₹93.14 Cr, and ₹97.17 Cr over the last twelve months. Earnings per share over the same trailing period were ₹39.54.

How much debt does Evonile Pharma have?

Evonile Pharma reported borrowings of ₹2.99 Cr at Mar 2026, against cash and equivalents of ₹666 Cr.

What is the free cash flow of Evonile Pharma?

Cash from operations was ₹47.05 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹45.92 Cr.

Loading…